Clinical trial · no report yet · Phase 3
DAWN-303
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- NCT07522073 ↗
- Recruiting
- Incyte Corporation
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 1 | |
| Podcasts | 1 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Solid Tumors
- Interventions
- INCB161734; Placebo; Investigator's choice of chemotherapy
- Arms
- INCB161734 plus chemotherapy · Experimental
- Placebo plus chemotherapy · Experimental
- Enrollment
- 588 (estimated)
- Primary outcomes
- Overall Survival (OS)
- Progression-free survival (PFS) by BICR
- Objective Response by BICR
- Sponsor
- Incyte Corporation with Qiagen Manchester Ltd
- Start
- Apr 9, 2026
- Primary completion
- Sep 15, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT07522073 · updated Oct 8, 2026